Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
Sign Up to like & getrecommendations! Published in 2018 at "AntiCancer Research"
DOI: 10.21873/anticanres.12697
Abstract: Background/Aim: Eribulin mesylate has been approved for advanced or metastatic breast cancers subjected to at least two previous chemotherapy regimens. The present multicenter, phase II, single-arm study assessed the efficacy and safety of a first-line… read more here.
Keywords: eribulin plus; plus trastuzumab; her2 positive; first line ... See more keywords